Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.50 |
| ▸ | HTR1D | P28221 | 9/20 | 0.50 |
| ▸ | HTR1B | P28222 | 9/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.50 |
| ▸ | BRD4 | O60885 | 6/20 | 0.36 |
| ▸ | SETDB1 | Q15047 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426904 | 0.88 | HTR1A (0.50) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL431052 | 0.79 | THRB (0.39) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL430475 | 0.79 | TP53 (0.45) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL433227 | 0.77 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL429130 | 0.77 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL429648 | 0.77 | HTR1A (0.52) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL429251 | 0.75 | HTR1A (0.52) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL428518 | 0.73 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL4169835 | 0.72 | HTR1A (0.47) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL430030 | 0.71 | HTR1A (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | HTR1A 7/4885HTR1D 11/4885HTR1B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.